MiMedx Group (MDXG) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MiMedx Group (MDXG) has outperformed Wave Life Sciences (WVE) over the past year, losing 34.9% versus a loss of 52.8%. Over five years, MDXG leads with a -31.7% price change compared with -32.6% for WVE. Wave Life Sciences is the larger company by market cap ($683.8 million vs $674.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDXG | WVE |
|---|---|---|
| Share price | $4.62 | $3.47 |
| Market cap | $674.22M | $683.76M |
| 1-day change | +0.22% | -1.98% |
| YTD return | -31.76% | -79.59% |
| 1-year return | -34.93% | -52.79% |
| 5-year return | -31.66% | -32.62% |
| P/E ratio (TTM) | 115.50 | — |
| Forward P/E | 23.10 | — |
| EPS (TTM) | $0.04 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.97 | $21.73 |
| 52-week low | $3.03 | $3.37 |
| Distance from 52-week high | -42.03% | -84.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +60.17% | +420.46% |
| Average volume | 1.23M | 3.12M |
| Shares outstanding | 145.93M | 197.05M |
| Employees | 808 | 317 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDXG has outperformed WVE by 17.9 percentage points over the past year.
About MiMedx Group
MDXG stock →MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare.
Health Care · Medical/Dental Instruments · 808 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
MDXG vs WVE FAQ
Which is bigger, MiMedx Group or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $683.76M compared with $674.22M for MiMedx Group (MDXG).
Which stock has performed better over the past year, MDXG or WVE?
MDXG returned -34.93% over the past 12 months, compared with -52.79% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are MiMedx Group and Wave Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for MiMedx Group and Biotechnology: Pharmaceutical Preparations for Wave Life Sciences.